マイクロRNAの市場規模、シェア、成長分析、製品・サービス別、用途別、最終用途別、地域別 - 産業予測、2024年～2031年

世界のマイクロRNAの市場規模は、2022年に12億米ドルとなり、2023年の13億5,000万米ドルから、2031年までには35億8,000万米ドルに成長し、予測期間（2024年～2031年）のCAGRは12.90％で成長する見通しです。

世界のマイクロRNA市場は、分子生物学、ゲノミクス、バイオインフォマティクスの進歩に後押しされ、最近顕著な成長を遂げています。マイクロRNA（miRNA）は、遺伝子発現の制御に不可欠な低分子ノンコーディングRNA分子であり、様々な疾患の貴重なバイオマーカーとして、また新たな治療法の潜在的な標的として位置づけられています。診断や治療におけるmiRNAの可能性とともに、疾患プロセスにおけるmiRNAの役割に対する理解が深まったことが、市場拡大の大きな原動力となっています。がん、心血管系疾患、神経疾患などの慢性疾患の増加は、miRNAが疾患の診断、予後、治療において有望であることから、この分野への研究や投資の増加につながり、この成長をさらに後押ししています。さらに、次世代シーケンシングやマイクロアレイプラットフォームのような技術の進歩がmiRNAのプロファイリングと検出を強化し、市場開拓を後押ししています。しかし、市場はいくつかの課題に直面しています。miRNAベースの治療薬や診断薬に関する複雑な規制状況を乗り切ることは大きなハードルであり、厳しい要件やコストのかかる臨床試験があります。miRNAベースの製品の安全性、有効性、特異性を確保することは非常に重要ですが、課題も多いです。また、miRNAの機能や生物学的システム内での相互作用についての理解が限られていることも研究を複雑にしています。miRNA治療薬の効果的な送達システムの開発も、標的への送達と安定性の必要性からくる課題です。このような障害があるにもかかわらず、世界のマイクロRNA市場には成長とイノベーションの大きな機会があり、技術の進歩、研究の増加、共同研究が新たなmiRNAベースの診断薬や治療法の開発を促進すると期待されています。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次・一次情報源
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主要な市場の考察

• 技術分析
• 市場のエコシステム
• サプライチェーン分析
• ケーススタディ分析
• PESTLE分析
• 規制情勢
• イノベーションマトリクス
• 主要な投資分析
• 主要な成功要因
• 競合の程度

マイクロRNA市場：製品・サービス別

• 市場概要
• サービス
  • タイプ
  • 分離・精製
  • miRNA cDNA合成
  • プロファイリング、ローカリゼーション、定量化
  • 機能分析
  • その他
  • 検体
  • 全血
  • 血清
  • プラズマ
  • FFPE
  • 新鮮凍結組織
  • その他
• 製品
  • 機器
  • テクノロジー
  • リアルタイムPCR
  • マイクロアレイ
  • 次世代シーズ
  • その他
  • ワークフロー
  • 分離・精製
  • miRNA cDNA合成
  • プロファイリング、ローカリゼーション、定量化
  • 関数解析とその他
  • その他
  • 消耗品
  • 検体
  • ワークフロー
  • 分離・精製
  • miRNA cDNA合成
  • プロファイリング、ローカリゼーション、定量化
  • 関数解析とその他
  • その他
  • 全血
  • 血清
  • プラズマ
  • FFPE
  • 新鮮凍結組織
  • その他

マイクロRNA市場：用途別

• 市場概要
• がん
• 感染症
• 免疫疾患
• 心血管疾患
• 神経疾患
• その他

マイクロRNA市場：最終用途別

• 市場概要
• バイオテクノロジー・製薬会社
• 学術機関・政府研究機関
• その他

マイクロRNA市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主要な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Thermo Fisher Scientific, Inc.（US）
• QIAGEN（Germany）
• NanoString Technologies, Inc.（US）
• Merck KGaA（Germany）
• Takara Bio, Inc.（Japan）
• BioGenex（US）
• GeneCopoeia, Inc.（US）
• New England Biolabs（US）
• Agilent Technologies, Inc.（US）
• Illumina, Inc.（US）
• Abcam plc（UK）
• Roche Holding AG（Switzerland）
• Arcturus Therapeutics Ltd.（US）
• Synthego Corporation（US）
• Bio-Techne Corporation（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Asuragen, Inc.（US）
• Cell Signaling Technology, Inc.（US）
• Molecular Cloud（China）
• Ribomed Biotechnologies, Inc.（US）
• Sirnaomics Inc.（US）

Global MicroRNA Market size was valued at USD 1.20 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 3.58 billion by 2031, growing at a CAGR of 12.90% during the forecast period (2024-2031).

The global microRNA market has experienced notable growth recently, fueled by advances in molecular biology, genomics, and bioinformatics. MicroRNAs (miRNAs) are small non-coding RNA molecules essential for regulating gene expression, positioning them as valuable biomarkers for various diseases and potential targets for new therapies. Increased understanding of miRNA's role in disease processes, alongside its potential in diagnostics and treatments, has significantly driven market expansion. The rise in chronic diseases, such as cancer, cardiovascular conditions, and neurological disorders, further supports this growth, as miRNAs show promise in disease diagnosis, prognosis, and treatment, leading to more research and investment in the field. Additionally, advancements in technologies like next-generation sequencing and microarray platforms have enhanced miRNA profiling and detection, boosting market development. However, the market faces several challenges. Navigating the complex regulatory landscape for miRNA-based therapeutics and diagnostics is a major hurdle, with stringent requirements and costly clinical trials. Ensuring the safety, efficacy, and specificity of miRNA-based products is critical but challenging. Limited understanding of miRNA functions and their interactions within biological systems also complicates research. Developing effective delivery systems for miRNA therapeutics is another challenge due to the need for targeted delivery and stability. Despite these obstacles, the global microRNA market holds substantial opportunities for growth and innovation, with technological advancements, increased research, and collaborative efforts expected to drive the development of new miRNA-based diagnostics and treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global MicroRNA market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global MicroRNA Market Segmental Analysis

Global MicroRNA Market is segmented by Products & Services, Application, End-use, and region. Based on Products & Services, the market is segmented into services, and products. Based on Application, the market is segmented into Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, and Others. Based on End-use, the market is segmented into Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global MicroRNA Market

Recent technological strides in genomics and molecular biology, particularly through next-generation sequencing and microarray platforms, have revolutionized the analysis of microRNAs. These advanced tools facilitate high-throughput examination, allowing researchers to identify and characterize microRNAs with greater efficiency. As a result, the capabilities of these technologies have spurred a surge in research activities, significantly contributing to the expansion of the microRNA market. The enhanced ability to analyze microRNAs has opened new avenues for discovery and innovation, further propelling market growth.

Restraints in the Global MicroRNA Market

Despite extensive research on microRNAs, their exact functions and mechanisms remain incompletely understood. This gap in knowledge presents challenges in pinpointing reliable and specific biomarkers, as well as in creating effective therapeutic strategies. The ongoing uncertainty surrounding microRNA biology complicates efforts to develop precise diagnostic and treatment options. Addressing these gaps is crucial for advancing the field and fully leveraging the potential of microRNAs in clinical applications.

Market Trends of the Global MicroRNA Market

Partnerships among biotechnology and pharmaceutical companies, academic research institutions, and government agencies are becoming more prevalent in the field of microRNA research. These collaborations combine the expertise, resources, and insights of various stakeholders, aiming to expedite the development and market introduction of microRNA-based products and solutions. By pooling their strengths, these collaborative efforts enhance the efficiency of research and development processes, driving innovation and accelerating the advancement of microRNA technologies. This collective approach supports the rapid commercialization and broader application of microRNA-based advancements.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Ecosystem of the Market
• Supply chain Analysis
• Case study Analysis
• PESTLE Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

MicroRNA Market by Products & Services

• Market Overview
• Services
  • Type
  • Isolation & Purification
  • miRNA cDNA Synthesis
  • Profiling, Localization, & Quantification
  • Functional Analysis
  • Others
  • Specimen
  • Whole Blood
  • Serum
  • Plasma
  • FFPE
  • Fresh Frozen Tissue
  • Others
• Products
  • Instruments
  • Technology
  • Real Time PCR
  • Microarray
  • NGS
  • Others
  • Workflow
  • Isolation & Purification
  • miRNA cDNA Synthesis
  • Profiling, Localization, & Quantification
  • Functional Analysis & Others
  • Others
  • Consumables
  • Specimen
  • Workflow
  • Isolation & Purification
  • miRNA cDNA Synthesis
  • Profiling, Localization, & Quantification
  • Functional Analysis & Others
  • Others
  • Whole Blood
  • Serum
  • Plasma
  • FFPE
  • Fresh Frozen Tissue
  • Others

MicroRNA Market by Application

• Market Overview
• Cancer
• Infectious Diseases
• Immunological Disorder
• Cardiovascular Disease
• Neurological Disease
• Others

MicroRNA Market by End-use

• Market Overview
• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Others

MicroRNA Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioGenex (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneCopoeia, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abcam plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcturus Therapeutics Ltd. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synthego Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asuragen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell Signaling Technology, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Molecular Cloud (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ribomed Biotechnologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirnaomics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments